* Corresponding Author
Potential skin problems of diabetes mellitus patients: a review
https://doi.org/10.19106/JMedSci005403202211 Iryani Andamari(1*), H. Bing Thio(2), Hardyanto Soebono(3)
(1) Department of Dermatology Erasmus University Medical Center, Rotterdam, The Netherlands
(2) Department of Dermatology Erasmus University Medical Center, Rotterdam, The Netherlands
(3) Department of Dermatology and Venereology, Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta
(*) Corresponding Author
Abstract
Diabetes mellitus (DM) is one of the common metabolic disorders, and a major part of chronic diseases, the prevalence of which tends to increase due to multifactor. Blood vessels, kidneys, lungs, and skin are among the organs that are affected. The first problem that arises, or commonly exists among one-third of diabetics, are problems with their skin, although skin lesions may develop along with the progress of the disease, or can occur during the later phase of DM. The prevalence and symptoms of skin problems in type 1 DM (T1DM) and type 2 DM (T2DM) are often unclear, and at the beginning of the course of the diseases they often go undiagnosed. Several theories regarding the pathophysiology of DM can be used as a logical reference for the early identification and diagnosis of skin problems, aimed at preventing the worsened condition. The use of skin autofluorescence (SAF) and AGEs reader in several cases of skin problems, can also be an important marker as an adjunct to predict the possibility and progressiveness of DM. Skin problems linked to patients with DM can be categorized as strongly related to diabetes, non-specific and related to DM, skin infection in DM, and skin problems due to diabetic medication. With the current COVID-19 pandemic, there are additional demands for more critical investigation of skin problems in patients with DM. The skin problems that occur in DM may need to be examined from the early stage and it is necessary to inhibit the progression of skin problems, as well as to consider the need for multidisciplinary DM therapy.
Keywords
Full Text:
PDFReferences
Ohiagu FO, Chikezie PC, Chikezie CM. Patophysiology of diabetes mellitus and its complication: metabolic events and control. Biomed Res Ther 2021; 8(3); 4243-57.
https://doi.org/10.15419/bmrat.v8i3.663
2.Park HY, Kim JH, Jung M, Chung CH, Hasham R, Park CS, et al. A long-standing hyperglycaemic condition impairs skin barrier by accelerating skin ageing process. Exp Dermatol 2011; 20(12):969-74.
https://doi.org/10.1111/j.1600-0625.2011.01364.x
3.Lima AL, Illing T, Schliemann S, Elsner P. Cutaneous manifestations of diabetes mellitus: a review. Am J Clin Dermatol 2017; 18:541-53.
https://doi.org/10.1007/s40257-017-0275-z
4.Scahchtel A, Kalus A. Diabetes and other endocrine disease. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, Orringer JS editors. Fitzpatrick's dermatology, 9th eds. New York: McGraw-Hill, 2019: 2493502.
5.Soelistijo SA, Lindarto D, Decroli E, Permana H, Sucipto KW, Kusnadi Y, et al. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2019. Perkumpulan Endokrinologi Indonesia 2019;4:1-17.
6.Shah A, Kanaya AM. Diabetes and associated complications in the South Asian population. Curr Cardiol Rep 2014; 16(5): 476.
https://doi.org/10.1007/s11886-014-0476-5
7.Golden SH, Yajnik C, Phatak S, Hanson RL, Knowler WC. Racial/ethnic differences in the burden of type 2 diabetes over the life course: a focus on the USA and India. Diabetologia 2019; 62(10):1751-60.
https://doi.org/10.1007/s00125-019-4968-0
8.Poorana B, Prasad PVS, Kaviarasan PK, Selvamuthukumaran S, Kannambal K. Impact of glycaemic control on the pattern of cutaneous disorders in diabetes mellitus - a hospital based case control study. J Clin Diagnos Res 2019; 13(2):WC01-5.
https://doi.org/10.7860/JCDR/2019/36742.12604
9.Macedo GMC, Nunes S, Barreto T. Skin disorders in diabetes mellitus: An epidemiology and physiopathology review. Diabetol Metab Synd 2016; 8(63):1-8.
https://doi.org/10.1186/s13098-016-0176-y
10.Makrantonaki E, Jiang D, Hossini AM, Nikolakis G, Wlaschek M, Scharffetter-Kochanek K, et al. Diabetes mellitus and the skin. Rev Endocr Metab Disord 2016;17(3):269-82.
https://doi.org/10.1007/s11154-016-9373-0
11.Chen J, Waqas K, Tan RC, Voortman T, Ikram MA, Nijsten TEC, et al. The association between dietary and skin advanced glycation end products: the Rotterdam Study. Am J Clin Nutr 2020;112(1):129-37.
https://doi.org/10.1093/ajcn/nqaa117
12.Dourmishev L, Pozharashka J. Dermatoses associated with diabetes mellitus. J Skin Stem Cell 2019; 6(4:e101180).
https://doi.org/10.5812/jssc.101180
13.Roslind S, Muhammed K, Sajeeth Kumar SG. Cutaneous manifestations in patients with type 2 diabetes mellitus and normal controls. J Skin Sex Trans Dis 2020; 2(1):26-30.
https://doi.org/10.25259/JSSTD_47_2019
14.Hattem SV, Boostma AH, Thio HB. Skin manifestations of diabetes. Cleveland Clin J Med 2008;75 (11):772-7.
https://doi.org/10.3949/ccjm.75.11.772
15.Bourke J. Skin Disorder in diabetes mellitus. In: Griffiths C, Barker J, Bleiker T, Chalmers L, Creamer D editors. Rook's textbook of dermatology 9th ed. London: Wiley Blackwell 2016: 1685-1691. www.rooksdermatology.com
16.Naik PP, Farrukh SN. Clinical significance of diabetic dermopathy. Diabetes Metab Syndr Obes 2020:13 4823-27.
https://doi.org/10.2147/DMSO.S286887
17.Bustan RS, Wasim D, Yderstraede KB, Bygum A. Spesific skin sign as a cutaneous marker of diabetes mellitus and the prediabetic state-a systematic review. Danish Med J 2017; 64(1): A5316:1-9
18.Barbato MT, Criado PR, Silva AK, Averbeck E, Guerine MB, Sá NB. Association of acanthosis nigricans and skin tags with insulin resistance. Ann Bras Dermatol 2012; 87(1):97-104.
https://doi.org/10.1590/S0365-05962012000100012
19.Goodfield MJD, Millard LG. The skin in diabetes mellitus. Diabetologia1988; 31:567-75.
https://doi.org/10.1007/BF00264762
20.Lefkovits Y, Adler A. Fatal squamous cell carcinoma from necrobiosis lipoidica diabeticorum in a diabetic patient. Endocrinol Diabetes Metab Case Rep 2019; 2019:19-0007.
https://doi.org/10.1530/EDM-19-0007
21.Sharpe GR, Yesudian PD. The Skin in Diabetes. In: Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ editors. Textbook of diabetes, 5th edition. London: Willey-Blackwell 2017.
22.Stefaniak AA, Chlebicka I, Szepietowski JC. Itch in diabetes: a common underestimated problem. Adv Dermatol Alergol 2019; 38(2): 1-7.
https://doi.org/10.5114/ada.2019.89712
23.Afsar B, Afsar EA. HbA1c is related with uremic pruritus in diabetic and nondiabetic hemodialysis patients. Renal Failure 2012;34(10):1264-9.
https://doi.org/10.3109/0886022X.2011.560401
24.Labib A, Rosen J, Yosipovitch G. Skin manifestations of diabetes mellitus. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.
https://www.ncbi.nlm.nih.gov/books/NBK481900/
25.Bose R, Kumar S. Dermatological manifestations in diabetes mellitus. IP Indian J Clinical Exp Dermatol 2020; 6(20):136-44.
https://doi.org/10.18231/j.ijced.2020.028
26.Wan MT, Shin DB, Hubbard RA, Noe MH, Mehta NN, Gelfand JM. Psoriasis and the risk of diabetes: A prospective population-based cohort study. J Am Acad Dermatol 2018; 78(2):315-22.e1.
https://doi.org/10.1016/j.jaad.2017.10.050
27.Abramczyk R, Queller JN, Rachfal AW, Schwartz SS. Diabetes and psoriasis: different sides of the same prism. Diabetes Metab Syndr Obes 2020;13:3571-7.
https://doi.org/10.2147/DMSO.S273147
28.Lønnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF. Association of psoriasis with the risk for type 2 diabetes mellitus and obesity. JAMA Dermatol 2016 1; 152(7):761-7.
https://doi.org/10.1001/jamadermatol.2015.6262
29.Tollefson MM, Van Houten HK, Asante D, Yao X, Maradit Kremers H. Association of psoriasis with comorbidity development in children with psoriasis. JAMA Dermatol 2018; 154(3):286-92.
https://doi.org/10.1001/jamadermatol.2017.5417
30.Akash MSH, Rehman K, Fiayyaz F, Sabir S, Khurshid M. Diabetes-associated infections: development of antimicrobial resistance and possible treatment strategies. Arch Microbiol 2020; 202(5):953-65.
https://doi.org/10.1007/s00203-020-01818-x
31.Tahapary DL, Ruiter de K, Martin I, Lieshout van L. Helminth infections and type 2 diabetes: a cluster-randomized placebo controlled SUGARSPIN trial in Nangapanda, Flores, Indonesia. BMC Infec Dis 2015;15:133.
https://doi.org/10.1186/s12879-015-0873-4
32.Sprawozdania. Final Report Summary. Helminth-induced regulatory mechanisms that prevent the onset of diabetes. 2016. final1-eu-summary-hu-bner-2015-final-report.pdf
33.Ugwueze CV, Ezeokpoa BC, Nnolima BI, Agim EA, Anikpo NC, Onyekachi KE. COVID-19 and diabetes mellitus: the link and clinical implications. Dubai Diabetes Endocrinol J. 2020; 26:69-77.
https://doi.org/10.1159/000511354
34.Zhang M, Gao W. COVID-19 and diabetes cutaneous comorbidity. Metabolism Open 7. 2020;100055. http://creativecommons.org/licenses/by-nc-nd/4.0/
https://doi.org/10.1016/j.metop.2020.100055
35.Marzano AV, Cassano N, Genovese G, Moltrasio C, Vena GA. Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue. Br J Dermatol. 2020; 183(3):431-42.
https://doi.org/10.1111/bjd.19264
36.Magro C, Nuovo G, Mulvey JJ, Laurence J, Harp J, Crowson AN. The skin as a critical window in unveiling the pathophysiologic principles of COVID-19. Clin Dermatol 2021; 39(6):934-65.
https://doi.org/10.1016/j.clindermatol.2021.07.001
37.Tan SW, Tam YC, Oh CC. Skin manifestations of COVID-19: A worldwide review. J Am Acad Dermatol 2021; 2:119-33.
https://doi.org/10.1016/j.jdin.2020.12.003
38.Dawood AS, Qadori MS. Cutaneous complications of insulin therapy in insulin dependent diabetes mellitus. Int J Adv Res Biol Sci 2018; 5(7):301-11.
39.Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne) 2017; 8:6.
https://doi.org/10.3389/fendo.2017.00006
40.Elangwe A, Katte JC, Tchapmi D, Figueras A, Mbanya JC. Adverse drug reactions to anti-diabetic drugs are commonest in patients whose treatment do not adhere to diabetes management clinical guidelines: cross-sectional study in a tertiary care service in sub-Saharan Africa. Eur J Clin Pharmacol 2020;76(11):1601-5.
https://doi.org/10.1007/s00228-020-02949-2
DOI: https://doi.org/10.19106/JMedSci005403202211
Article Metrics
Abstract views : 839
| 
views : 2143
Copyright (c) 2022 Iryani - Andamari
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.